NNVC

NanoViricides, Inc.

1.11 USD

Last updated Dec 3, 00:49 UTC

Yesterday HIGH

$1.2

Yesterday LOW

$1.11

52w HIGH

$2

52w LOW

$1

EPS

-0.17

PE

-6.53

Next Earnings

Feb 13, 2024

Overview News Government Trades

NanoViricides, Inc. stock is down -2.63% since 30 days ago. The next earnings date is Feb 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 26.32% of the previous 18 December’s closed higher than November.

NanoViricides, Inc. discovers, develops, and commercializes drugs for the treatment of viral infections. Company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction. Company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide.

Stock Exchange

NYSE MKT

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Reno, United States Of America

Website

nanoviricides.com

richadhand@benzinga.com

Thu Jun 1, 2023

EF Hutton Assumes Nanoviricides at Buy, Announces Price Target of $5.25

EF Hutton analyst Constantine Davides assumes Nanoviricides (AMEX:NNVC) with a Buy rating and announces Price Target of $5.25.
Benzinga Newsdesk

Tue May 16, 2023

NanoViricides Says Clinical Trials Of Broad-Spectrum COVID Drug About To Begin

The company estimates that it has sufficient funds to complete initial human clinical trials for lead drug candidate NV-CoV-2 for the treatment of SARS-CoV-2 infection that causes COVID and also "long
Charles Gross

Tue Apr 25, 2023

NanoViricides is Expanding its Broad-Spectrum Antiviral Program To Explore Further Antiviral Applications Of Its COVID Clinical Drug Ingredient

NanoViricides, Inc. (NYSE American: NNVC) reports that it is exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company's COVID clinical drug candidate.
richadhand@benzinga.com

Tue Apr 18, 2023

EF Hutton Reiterates Buy on Nanoviricides, Maintains $5.25 Price Target

EF Hutton analyst Constantine Davides reiterates Nanoviricides (AMEX:NNVC) with a Buy and maintains $5.25 price target.
Charles Gross

Mon Apr 17, 2023

NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate

NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage global leader in nanomedicines against viruses, announced today that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt.
Benzinga Insights

Fri Apr 7, 2023

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights

Thu Apr 6, 2023

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Newsdesk

Tue Apr 4, 2023

Nanoviricides Has Executed A License Agreement With Karveer Meditech Pvt. Ltd Based In India, To Commercialize The Company's COVID Drugs In India

To enable commercialization, Karveer has undertaken Clinical Development and Evaluation and is sponsoring these two drugs in India for this purpose. Karveer has represented to NanoViricides that it has successfully
Lisa Levin

Tue Feb 28, 2023

uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday

UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market trading.
richadhand@benzinga.com

Tue Feb 28, 2023

EF Hutton Maintains Buy on Nanoviricides, Lowers Price Target to $5.25

EF Hutton analyst Constantine Davides maintains Nanoviricides (AMEX:NNVC) with a Buy and lowers the price target from $8.5 to $5.25.